

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (Withdrawn) An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polynucleotide fragment of SEQ ID NO:40 or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:209782, which is hybridizable to SEQ ID NO:40;

(b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:161 or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:209782, which is hybridizable to SEQ ID NO:40;

(c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:161 or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:209782, which is hybridizable to SEQ ID NO:40;

(d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:161 or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:209782, which is hybridizable to SEQ ID NO:40;

(e) a polynucleotide encoding a polypeptide of SEQ ID NO:161 or the cDNA sequence included in ATCC Deposit No:209782, which is hybridizable to SEQ ID NO:40, having biological activity;

(f) a polynucleotide which is a variant of SEQ ID NO:40;

(g) a polynucleotide which is an allelic variant of SEQ ID NO:40;

(h) a polynucleotide which encodes a species homologue of the SEQ ID NO:161;

(i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

2. (Withdrawn) The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.
3. (Withdrawn) The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:161 or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:209782, which is hybridizable to SEQ ID NO:40.
4. (Withdrawn) The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:40 or the cDNA sequence included in ATCC Deposit No:209782, which is hybridizable to SEQ ID NO:40.
5. (Withdrawn) The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
6. (Withdrawn) The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
7. (Withdrawn) A recombinant vector comprising the isolated nucleic acid molecule of claim 1.
8. (Withdrawn) A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.
9. (Withdrawn) A recombinant host cell produced by the method of claim 8.
10. (Withdrawn) The recombinant host cell of claim 9 comprising vector sequences.
- 11.-12. (Canceled).

13. (Withdrawn) An isolated antibody that binds specifically to the isolated polypeptide of claim 11.
14. (Withdrawn) A recombinant host cell that expresses the isolated polypeptide of claim 11.
15. (Withdrawn – Currently Amended) A method of making an isolated polypeptide comprising:
- (a) culturing ~~the a~~ recombinant host cell ~~of claim 14~~ under conditions such that said polypeptide is expressed, wherein the recombinant host cell expresses a polypeptide encoded by a sequence selected from the group consisting of:
- 1) SEQ ID NO: 347;
  - 2) SEQ ID NO: 348;
  - 3) SEQ ID NO: 349;
  - 4) Thr-41 to Gly-47 of SEQ ID NO: 161;
  - 5) Pro-170 to Asp-176 of SEQ ID NO: 161;
  - 6) Leu-257 to Trp-262 of SEQ ID NO: 161;
  - 7) Gln-276 to Ser-283 of SEQ ID NO: 161;
  - 8) Arg-323 to Leu-330 of SEQ ID NO: 161;
  - 9) Pro-362 to Val-374 of SEQ ID NO: 161;
  - 10) a combination of two or more of (a) – (i); and
  - 11) a polypeptide comprising a first region and a second region,
- wherein the first region is selected from the group consisting of the polypeptides (a)-(j);  
and wherein the second region comprises a heterologous polypeptide sequence; and
- (b) recovering said polypeptide.
16. (Canceled).

17. (Withdrawn – Currently Amended) A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of ~~the polynucleotide of claim 1.~~ an isolated polynucleotide which encodes a polypeptide selected from the group consisting of:

- a) SEQ ID NO: 347;
- b) SEQ ID NO: 348;
- c) SEQ ID NO: 349;
- d) Thr-41 to Gly-47 of SEQ ID NO: 161;
- e) Pro-170 to Asp-176 of SEQ ID NO: 161;
- f) Leu-257 to Trp-262 of SEQ ID NO: 161;
- g) Gln-276 to Ser-283 of SEQ ID NO: 161;
- h) Arg-323 to Leu-330 of SEQ ID NO: 161;
- i) Pro-362 to Val-374 of SEQ ID NO: 161;
- j) a combination of two or more of (a) – (i); and
- k) a polypeptide comprising a first region and a second region,

wherein the first region is selected from the group consisting of the polypeptides (a)-(j);  
and wherein the second region comprises a heterologous polypeptide sequence.

18. (Withdrawn – Currently Amended) A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of ~~the polypeptide of claim 11.~~ an isolated polypeptide selected from the group consisting of:

- a) SEQ ID NO: 347;
- b) SEQ ID NO: 348;
- c) SEQ ID NO: 349;
- d) Thr-41 to Gly-47 of SEQ ID NO: 161;
- e) Pro-170 to Asp-176 of SEQ ID NO: 161;
- f) Leu-257 to Trp-262 of SEQ ID NO: 161;
- g) Gln-276 to Ser-283 of SEQ ID NO: 161;
- h) Arg-323 to Leu-330 of SEQ ID NO: 161;
- i) Pro-362 to Val-374 of SEQ ID NO: 161;
- j) a combination of two or more of (a) – (i); and
- k) a polypeptide comprising a first region and a second region,

wherein the first region is selected from the group consisting of the polypeptides (a)-(j);  
and wherein the second region comprises a heterologous polypeptide sequence.

19. (Withdrawn) A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the antibody of claim 13.

20. (Withdrawn) A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
- (a) determining the presence or absence of a mutation in the polynucleotide of claim 1;
- and
- (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.
21. (Withdrawn) A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
- (a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and
  - (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.
22. (Withdrawn) A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
- (a) using the antibody of claim 13 to determine the presence or amount of expression of a polypeptide that specifically binds said antibody; and
  - (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.
23. (Withdrawn) A method for identifying a binding partner to the polypeptide of claim 11 comprising:
- (a) contacting the polypeptide of claim 11 with a binding partner; and
  - (b) determining whether the binding partner effects an activity of the polypeptide.
24. (Withdrawn) The gene corresponding to the cDNA sequence encoding SEQ ID NO:161.

25. (Withdrawn) A method of identifying an activity in a biological assay, wherein the method comprises:
- (a) expressing SEQ ID NO:40 in a cell;
  - (b) isolating the supernatant;
  - (c) detecting an activity in a biological assay; and
  - (d) identifying the protein in the supernatant having the activity.
26. (Withdrawn) The product produced by the method of claim 23.
27. (New) An isolated polypeptide selected from the group consisting of:
- a) SEQ ID NO: 347;
  - b) SEQ ID NO: 348;
  - c) SEQ ID NO: 349; and
  - d) a combination of two or more of (a)-(c).
28. (New) An isolated polypeptide differing from the polypeptide of claim 27 by a single amino acid, wherein the polypeptide is capable of generating or selecting an antibody that specifically binds to the polypeptide of claim 27.
29. (New) An isolated polypeptide selected from the group consisting of:
- a) Thr-41 to Gly-47 of SEQ ID NO: 161;
  - b) Pro-170 to Asp-176 of SEQ ID NO: 161;
  - c) Leu-257 to Trp-262 of SEQ ID NO: 161;
  - d) Gln-276 to Ser-283 of SEQ ID NO: 161;
  - e) Arg-323 to Leu-330 of SEQ ID NO: 161;
  - f) Pro-362 to Val-374 of SEQ ID NO: 161; and
  - g) a combination of two or more of (a) – (f).

30. (New) An isolated polypeptide differing from the polypeptide of claim 29 by a single amino acid, wherein the polypeptide is capable of generating or selecting an antibody that specifically binds to the polypeptide of claim 29.

31. (New) An isolated polypeptide comprising a first region and a second region, wherein the first region is selected from the group consisting of:

- a) SEQ ID NO: 347;
- b) SEQ ID NO: 348;
- c) SEQ ID NO: 349;
- d) Thr-41 to Gly-47 of SEQ ID NO: 161;
- e) Pro-170 to Asp-176 of SEQ ID NO: 161;
- f) Leu-257 to Trp-262 of SEQ ID NO: 161;
- g) Gln-276 to Ser-283 of SEQ ID NO: 161;
- h) Arg-323 to Leu-330 of SEQ ID NO: 161;
- i) Pro-362 to Val-374 of SEQ ID NO: 161; and
- j) a combination of two or more of (a) – (i);

wherein the second region comprises a heterologous polypeptide sequence.